Source-grounded facts extracted from Dermata Therapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Dermata Therapeutics, Inc. shareholders approved Approval of the adjournment of the Annual Meeting to solicit additional votes (Adjournment Proposal).
“The Adjournment Proposal was approved based upon the following votes: For Against Abstain 1,269,857 21,137 14,821”
Dermata Therapeutics, Inc. shareholders approved Approval of an amendment to the 2021 Plan to increase the maximum aggregate number of shares reserved for issuance to 402,214 shares (Plan Amendment Proposal).
“The Plan Amendment Proposal was approved based upon the following votes: For Against Abstain Broker Non-Votes 1,243,540 47,441 14,834 1,068,656”
Dermata Therapeutics, Inc. shareholders approved Approval of the repricing of warrants exercisable for up to 120,734 shares of Common Stock (Warrant Repricing Proposal).
“The Warrant Repricing Proposal was approved based upon the following votes: For Against Abstain Broker Non-Votes 439,573 21,203 845,039 1,068,656”
Dermata Therapeutics, Inc. shareholders approved Approval of the issuance of shares of Common Stock underlying certain warrants in an amount equal to or in excess of 20% of the Common Stock outstanding immediately prior to the issuance of such warrants (Issuance Proposal).
“The Issuance Proposal was approved based upon the following votes: For Against Abstain Broker Non-Votes 315,477 22,696 967,642 1,068,656”
Dermata Therapeutics, Inc. shareholders approved Ratification of the appointment of CBIZ CPAs P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.
“The Auditor Proposal was approved based upon the following votes: For Against Abstain 2,329,537 43,122 1,812”
Dermata Therapeutics, Inc. shareholders approved Election of three Class II directors.
“The stockholders elected David Hale, Steven Mento, Ph.D. and Brittany Bradrick as Class II directors to serve until the 2029 annual meeting and until their successors have been duly elected and qualified. The votes were cast for this matter as follows: Nominee For Withheld Broker Non-Votes David Hale 1,258,269 47,546 1,068,656 Steven Mento Ph.D. 1,258,871 46,944 1,068,656 Brittany Bradrick 1,262,134 43,681 1,068,656”
Dermata Therapeutics, Inc. reported financial results for first quarter ended March 31, 2026.
“On May 13, 2026, Dermata Therapeutics, Inc. (the “Company”) issued a press release disclosing certain information regarding its results of operations for the quarter ended March 31, 2026, and provided a corporate update.”
Dermata Therapeutics, Inc. reported financial results for year ended December 31, 2025.
“Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Year Ended 2025”
Dermata Therapeutics, Inc. engaged CBIZ CPAs P.C. as its auditor.
“On February 2, 2026, the Audit Committee approved the appointment of CBIZ CPAs P.C., (formerly known as Mayer Hoffman McCann P.C.) (“CBIZ CPAs”) as the Company’s new independent registered public accounting firm.”
Dermata Therapeutics, Inc. dismissed Baker Tilly US, LLP as its auditor.
“On January 30, 2026, Dermata Therapeutics, Inc. (the “Company”) notified Baker Tilly US, LLP (formerly Moss Adams LLP) (“Baker Tilly”) that Baker Tilly would be dismissed as the Company’s independent registered public accounting firm.”
Dermata Therapeutics, Inc. issued Warrants to purchase up to an aggregate of 1,470,588 shares of Common Stock of warrant to company insiders (CEO and CFO) for included in the aggregate purchase price of approximately $1.5 million.
“These company insiders purchased an aggregate of 735,294 Shares and Warrants to purchase up to an aggregate of 1,470,588 shares of Common Stock, for an aggregate purchase price of approximately $1.5 million.”
Dermata Therapeutics, Inc. issued 735,294 Shares of common stock to company insiders (CEO and CFO) for aggregate purchase price of approximately $1.5 million.
“Company insiders, including the Company's Chief Executive Officer and Chief Financial Officer, participated in the Private Placement. These company insiders purchased an aggregate of 735,294 Shares and Warrants to purchase up to an aggregate of 1,470,588 shares of Common Stock, for an aggregate purchase price of approximately $1.5 million.”
Dermata Therapeutics, Inc. issued Series C Warrants to purchase up to 2,022,062 shares of Common Stock and Series D Warrants to purchase up to 2,022,062 shares of Common Stock of warrant to institutional and accredited investors for issued as part of units with Shares or Pre-Funded Warrants at purchase price of $2.04 or $2.039 per unit.
“Warrants ” together with the Series C Warrants, the “ Warrants ”) to purchase up to 2,022,062 shares of Common Stock. The purchase price per Share and accompanying Warrants was $2.04 and the purchase price per Pre-Funded Warrant and accompanying Warrant was $2.039. The Warrants have an exercise price of $2.04 per share. The Pre-Funded Warrants are exercisable”
Dermata Therapeutics, Inc. issued Pre-Funded Warrants to purchase up to 537,750 shares of Common Stock of warrant to institutional and accredited investors for $2.039 per Pre-Funded Warrant and accompanying warrant.
“Warrants ” together with the Series C Warrants, the “ Warrants ”) to purchase up to 2,022,062 shares of Common Stock. The purchase price per Share and accompanying Warrants was $2.04 and the purchase price per Pre-Funded Warrant and accompanying Warrant was $2.039. The Warrants have an exercise price of $2.04 per share. The Pre-Funded Warrants are exercisable”
Dermata Therapeutics, Inc. issued 1,484,312 shares of common stock to institutional and accredited investors for $2.04 per share and accompanying warrants.
“Warrants ” together with the Series C Warrants, the “ Warrants ”) to purchase up to 2,022,062 shares of Common Stock. The purchase price per Share and accompanying Warrants was $2.04 and the purchase price per Pre-Funded Warrant and accompanying Warrant was $2.039. The Warrants have an exercise price of $2.04 per share. The Pre-Funded Warrants are exercisable”
Dermata Therapeutics, Inc. amended Warrant Amendment Agreements with certain holders of the Company’s outstanding warrants that participated as investors in the Private Placement (effective 2025-12-23).
“Pursuant to warrant amendment agreements each dated December 23, 2025, among the Company and certain holders of the Company’s outstanding warrants that participated as investors in the Private Placement (collectively, the “ Warrant Amendment Agreements ”), the Company amended certain outstanding warrants to purchase up to an aggregate of 120,734 share”
Dermata Therapeutics, Inc. entered into Engagement Letter with H.C. Wainwright & Co., LLC valued at 7.0% of the aggregate gross proceeds of the Private Placement raised from outside institutional and.
“Pursuant to the Engagement Letter, the Company paid Wainwright (i) a cash fee equal to (x) 7.0% of the aggregate gross proceeds of the Private Placement raised from outside institutional and accredited investors, and (y) 3.5% of the aggregate gross proceeds of the Private Placement raised from insider investors, (iii) a management fee of 1.0% of the aggregate gross proceeds of the Private Placement, (iv) a non-accountable expense allowance of $25,000, and (v) an out-of-pocket expense allowance of $40,000.”
Dermata Therapeutics, Inc. entered into Registration Rights Agreement with the investors (effective 2025-12-23).
“In connection with the Private Placement, the Company entered into a registration rights agreement (the “ Registration Rights Agreement ”), dated as of December 23, 2025, with the investors, pursuant to which the Company agreed to prepare and file a registration statement with the Securities and Exchange Commission (the “ SEC ”) registering the resale of the Shares and the shares of Common Stock underlying the Pre-Funded Warrants and the Warrants no later than thirty (30) days after the date of the Registration Rights Agreement (the “ Registration Statement ”), and to use its best efforts to have the registration statement declared effective as promptly as practical thereafter, and in any event no later than sixty (60) days following the date of the Registration Rights Agreement (or ninety (90) days following the date of the Registration Rights Agreement in the event of a “full review” by the SEC).”
Dermata Therapeutics, Inc. entered into Purchase Agreement with certain institutional and accredited investors valued at purchase price per Share and accompanying Warrants was $2.04 (effective 2025-12-23).
“On December 23, 2025, Dermata Therapeutics, Inc. (the “ Company ”) entered into a securities purchase agreement (the “ Purchase Agreement ”) with certain institutional and accredited investors for the issuance and sale in a private placement (the “ Private Placement ”) of (i) 1,484,312 shares (the “ Shares ”) of the Company’s common stock, par value $0.0001 per share (the “ Common Stock ”), (ii) pre-funded warrants (“ Pre-Funded Warrants ”) to purchase up to 537,750 shares of Common Stock, at an exercise price of $0.001 per share, (iii) series C warrants (the “ Series C Warrants ”) to purchase up to 2,022,062 shares of Common Stock, and (iv) series D warrants (the “ Series D Warrants ” together with the Series C Warrants, the “ Warrants ”) to purchase up to 2,022,062 shares of Common Stock.”
Dermata Therapeutics, Inc.: Certificate of Amendment filed to effect a one-for-10 reverse stock split of common stock (effective 2025-08-01).
“On July 30, 2025, Dermata Therapeutics, Inc. (the “Company”) filed a Certificate of Amendment to the Company’s Amended and Restated Certificate of Incorporation, as amended, with the Secretary of State of the State of Delaware (the “Certificate of Amendment”), which will effect, at 12:01 a.m. Eastern Time, on August 1, 2025, a one-for-10 (1:10) reverse stock split (the “Reverse Stock Split”) of the Company’s issued and outstanding shares of common stock, par value $0.0001 per share (the “Common Stock”).”
Dermata Therapeutics, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).
“July 2, 2025, the Panel notified the Company that it has granted Company’s request for an exception until August 14, 2025, to demonstrate compliance with the Minimum Bid Price Requirement (the “Exception”). Pursuant to the Exception, the Company is required to provide the Panel with prompt notification of any significant events that occur, including any event that may call into question the Company’s ability to satisfy the terms of the Exception. The Company is actively pursuing measures to regain compliance with the Minimum Bid Price Requirement, including seeking shareholder approval for a r”
Dermata Therapeutics, Inc. engaged Baker Tilly US, LLP as its auditor.
“In connection with the notification of the merger, the audit committee of the Company’s Board of Directors approved the appointment of Baker Tilly, as the successor to Moss Adams, as the Company’s independent registered public accounting firm.”
Dermata Therapeutics, Inc. received a nasdaq compliance regained notice regarding stockholders equity (rules 5550(b)(1)).
“May 14, 2025, the Company received a letter from the Staff indicating that as of May 14, 2025, the Company has regained compliance with the Stockholder’s Equity Requirement and the matter is now closed. Minimum Bid Price On May 14, 2025, the Company received a written notice (the “Notice”) from the Staff indicating that the Company is not in compliance with the $1.00 Minimum Bid Price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market (the “Bid Price Requirement”). The Staff further indicated that, based upon the Company’s implementation”
Dermata Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
“May 14, 2025, the Company received a letter from the Staff indicating that as of May 14, 2025, the Company has regained compliance with the Stockholder’s Equity Requirement and the matter is now closed. Minimum Bid Price On May 14, 2025, the Company received a written notice (the “Notice”) from the Staff indicating that the Company is not in compliance with the $1.00 Minimum Bid Price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market (the “Bid Price Requirement”). The Staff further indicated that, based upon the Company’s implementation”
Dermata Therapeutics, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).
“March 25, 2025, Dermata Therapeutics, Inc. (the “Company”) received a letter (the “Letter”) from The Nasdaq Capital Market (“Nasdaq”) notifying the Company that it is no longer in compliance with the minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market. Nasdaq Listing Rule 5550(b)(1) requires listed companies to maintain stockholders’ equity of at least $2.5 million. In the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, the Company reported stockholders’ equity of approximately $1.6 million, which is below the required minimum.”
Dermata Therapeutics, Inc. entered into Inducement Letter with holders of Existing Warrants valued at aggregate gross proceeds of approximately $2.66 million (effective 2024-05-17).
“On May 17, 2024, Dermata Therapeutics, Inc. (the “ Company ”) entered into inducement offer letter agreements (each, an “ Inducement Letter ”) with holders (the “ Holders ”) of certain of the Company's existing warrants”
Dermata Therapeutics, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).
“May 14, 2024, the Company received a letter from Nasdaq advising that the Company had been granted a 180-day extension to November 11, 2024, to regain compliance with the Minimum Bid Price Requirement. As previously disclosed on May 14, 2024, in order to regain compliance with the Minimum Bid Price Requirement, the Company has filed a Certificate of Amendment to the Company’s Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware which will effect, at 12:01 a.m. Eastern Time, on May 16, 2024, a one-for-fifteen (1:15) reverse stock split of the Co”
Dermata Therapeutics, Inc. reported first quarter ended March 31, 2024 results: net income $3.1 million of net loss.
“The decrease in cash and cash equivalents resulted from $3.1 million of net loss for the quarter ended March 31, 2024, and $0.2 million of decreased accrued liabilities, offset by $0.6 million in stock-based compensation expense.”
Dermata Therapeutics, Inc.: Effected a one-for-fifteen reverse stock split by filing a Certificate of Amendment to the Amended and Restated Certificate of Incorporation (effective 2024-05-16).
“On May 14, 2024, Dermata Therapeutics, Inc. (the “Company”) filed a Certificate of Amendment to the Company’s Amended and Restated Certificate of Incorporation, as amended, with the Secretary of State of the State of Delaware (the “Certificate of Amendment”), which will effect, at 12:01 a.m. Eastern Time, on May 16, 2024, a one-for-fifteen (1:15) reverse stock split (the “Reverse Stock Split”) of the Company’s issued and outstanding shares of common stock, par value $0.0001 per share (the “Common Stock”).”
Dermata Therapeutics, Inc. shareholders approved Election of three Class III directors.
“The matters voted on at the Annual Meeting were: (1) the election of three Class III directors”
Dermata Therapeutics, Inc. reported financial results for full year ended December 31, 2023.
“On March 21, 2024, Dermata Therapeutics, Inc. (the “Company”) issued a press release disclosing certain information regarding its results of operations for the fiscal year ended December 31, 2023.”
Dermata Therapeutics, Inc. shareholders approved The approval of the adjournment of the Special Meeting to a later date or dates, if necessary or appropriate, to permit further solicitation and vote of proxies (Adjournment Proposal) at the 2024-01-12 meeting.
“Proposal No. 3 : The Adjournment Proposal was approved by a vote of stockholders as follows: Votes For Votes Against Abstentions Broker Non-Votes 788,925 4,893 422 485,871”
Dermata Therapeutics, Inc. shareholders approved The ratification of the appointment of Moss Adams LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 (Auditor Proposal) at the 2024-01-12 meeting.
“Proposal No. 2 : The Auditor Proposal was approved by a vote of stockholders as follows: Votes For Votes Against Abstentions Broker Non-Votes 1,269,895 9,551 665 0”
Dermata Therapeutics, Inc. shareholders approved The authorization for purposes of complying with Nasdaq Listing Rule 5635(d) of the issuance of shares of Common Stock underlying certain warrants (Issuance Proposal) at the 2024-01-12 meeting.
“Proposal No. 1 : The Issuance Proposal was approved by a vote of stockholders as follows: Votes For Votes Against Abstentions Broker Non-Votes 789,001 5,008 231 485,871”
Dermata Therapeutics, Inc. entered into Engagement Letter with H.C. Wainwright & Co., LLC valued at Cash fee equal to 7.0% of aggregate gross proceeds from Holder's exercise of Existing Warrants, plus (effective 2023-09-30).
“The Company engaged H.C. Wainwright & Co., LLC (the “ Placement Agent ”) to act as its exclusive placement agent in connection with the transactions summarized above and has agreed to pay the Placement Agent a cash fee equal to 7.0% of the aggregate gross proceeds received from the Holder’s exercise of its Existing Warrants, as well as a management fee equal to 1.0% of the gross proceeds from the exercise of the Existing Warrants, pursuant to that certain engagement letter, by and between the Company and the Placement Agent, dated as of September 30, 2023 (the “ Engagement Letter ”).”
Dermata Therapeutics, Inc. entered into Inducement Letter with Holder of Existing Warrants valued at Aggregate gross proceeds of approximately $2.26 million from exercise of Existing Warrants (effective 2023-11-16).
“On November 16, 2023, Dermata Therapeutics, Inc. (the “ Company ”) entered into an inducement offer letter agreement (the “ Inducement Letter ”) with a holder (the “ Holder ”) of certain of its existing warrants to purchase up to an aggregate of 3,472,095 shares of the Company’s common stock, par value $0.0001 per share (“ Common Stock ”), issued to the Holder on (i) April 25, 2022 (as amended on March 20, 2023, the “ April 2022 Warrants ”) and (ii) March 20, 2023 (the “ March 2023 Warrants ” and together with the April 2022 Warrants, the “ Existing Warrants ”).”
Dermata Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
“November 15, 2023, Dermata Therapeutics, Inc. (the “ Company ”) received a written notice (the “ Notice ”) from the Listing Qualifications Department of The Nasdaq Stock Market (“ Nasdaq ”) indicating that the Company is not in compliance with the $1.00 Minimum Bid Price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market (the “ Bid Price Requirement ”). The Notice does not result in the immediate delisting of the Company’s common stock from The Nasdaq Capital Market. The Nasdaq Listing Rules require listed securities to maintain a minimum”
Dermata Therapeutics, Inc. reported financial results for third quarter ended September 30, 2023.
“Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results”
Dermata Therapeutics, Inc. engaged Moss Adams LLP as its auditor.
“On November 9, 2023, the Audit Committee appointed Moss Adams LLP (“ Moss Adams ”) as the Company’s new independent registered public accounting firm for the fiscal year ending December 31, 2023.”
Dermata Therapeutics, Inc. reported the second quarter ended June 30, 2023 results: revenue $8.4 million in cash and cash equivalents.
“to pursue partnership discussions for its DMT410 program for the topical delivery of botulinum toxin. Second Quarter 2023 Financial Results As of June 30, 2023, Dermata had $8.4 million in cash and cash equivalents, compared to $6.2 million as of December 31, 2022. The increase in cash and cash equivalents resulted from $5.7 million net proceeds from the”
Dermata Therapeutics, Inc. shareholders approved Ratification of appointment of Mayer Hoffman McCann P.C. as independent registered public accounting firm at the 2023-12-31 meeting.
“The proposal to ratify the appointment of Mayer Hoffman McCann P.C. as the Company’s independent registered public accounting firm for the Company’s fiscal year ending December 31, 2023, was approved based upon the following votes: For Against Abstain 1,432,787.75 36,347 837”
Dermata Therapeutics, Inc. shareholders approved Election of three Class II directors.
“The votes were cast for this matter as follows: Nominee For Against Broker Non-Votes David Hale 463,516.75 255,950 750,505 Steven J. Mento, Ph.D. 463,698.75 255,768 750,505 Brittany Bradrick 687,187.75 32,279 750,505”
Dermata Therapeutics, Inc. entered into Purchase Agreement with the investors named on the signature pages thereto valued at approximately $1.8 million (effective 2023-05-23).
“On May 23, 2023, Dermata Therapeutics, Inc. (the “ Company ”) entered into a securities purchase agreement (the “ Purchase Agreement ”) with the investors named on the signature pages thereto (collectively, the “ Purchasers ”), pursuant to which the Company agreed to sell and issue, in a registered direct offering, an aggregate of (i) 458,555 shares (the “ Shares ”) of common stock, par value $0.0001, of the Company (“ Common Stock ”) at a purchase price of $2.285 per Share and accompanying Warrant (as defined below), and (ii) 342,322 pre-funded warrants (the “ Pre-Funded Warrants ”) to purchase up to an aggregate of 342,322 shares of Common Stock (the “ Pre-Funded Warrant Shares ”) at a purchase price of $2.2849 per Pre-Funded Warrant and accompanying Warrant, for aggregate gross proceeds to the Company of approximately $1.8 million”
Dermata Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2023.
“reported financial results for the first quarter ended March 31, 2023.”
Dermata Therapeutics, Inc. entered into Purchase Agreement with an investor valued at approximately $4.2 million (effective 2023-03-16).
“On March 16, 2023, Dermata Therapeutics, Inc. (the " Company ") entered into a securities purchase agreement with an investor (the " Purchase Agreement ") pursuant to which the Company agreed to sell, in a best efforts public offering (the " Offering ") priced at the market under Nasdaq rules, an aggregate of (i) 85,000 shares (the " Shares ") of common stock, par value $0.0001 per share (the " Common Stock "), of the Company, (ii) pre-funded warrants (the " Pre-Funded Warrants ") to purchase up to an aggregate of 1,533,123 shares of Common Stock (the " Pre-Funded Warrant Shares "), (iii) Series A warrants (the " Series A Common Warrants ") to purchase up to an aggregate of 1,618,123 shares of Common Stock (the " Series A Warrant Shares "), and (iv) Series B warrants (the " Series B Common Warrants " and collectively with the Series A Warrants, the " Warrants ") to purchase up to an aggregate of 1,618,123 shares of Common Stock (the " Series B Warrant Shares " and together with the Ser”
Dermata Therapeutics, Inc.: Effect a 1-for-16 reverse stock split via Certificate of Amendment to Amended and Restated Certificate of Incorporation (effective 2023-03-14).
“On March 13, 2023, Dermata Therapeutics, Inc. (the “Company”) filed a Certificate of Amendment to the Company’s Amended and Restated Certificate of Incorporation, as amended, with the Secretary of State of the State of Delaware (the “Certificate of Amendment”), which will effect, at 12:01 a.m. Eastern Time, on March 14, 2023, a 1-for-16 reverse stock split (the “Reverse Stock Split”) of the Company’s issued and outstanding shares of common stock, par value $0.0001 per share (the “Common Stock”).”
Dermata Therapeutics, Inc. reported financial results for the year ended December 31, 2022.
“On February 21, 2023, Dermata Therapeutics, Inc. (the “Company”) issued a press release disclosing certain information regarding its results of operations for the fiscal year ended December 31, 2022.”
Dermata Therapeutics, Inc. shareholders approved Approval of the adjournment of the special meeting to the extent there are insufficient votes to approve the reverse stock split proposal at the 2023-02-08 meeting.
“Proposal No. 2 : The Adjournment Proposal was approved by a vote of stockholders as follows: Votes For Votes Against Abstentions 7,681,932 87,554 28,592”
Dermata Therapeutics, Inc. shareholders approved Adoption and approval of an amendment to the Company's Amended and Restated Certificate of Incorporation to effect a reverse stock split at a ratio from one-for-two to one-for-forty, with the exact ratio determined by the board at the 2023-02-08 meeting.
“Proposal No. 1 : The Reverse Stock Split Proposal was approved by a vote of stockholders as follows: Votes For Votes Against Abstentions 7,622,928 135,481 39,669”
Dermata Therapeutics, Inc. received a nasdaq noncompliance notice notice regarding minimum bid price (rules 5550(a)(2)).
“December 15, 2022 the Company received a letter from Nasdaq advising that the Company had been granted a 180-day extension to June 12, 2023, to regain compliance with the Minimum Bid Price Requirement. The Company will continue to monitor the closing bid price of its Common Stock and may, if appropriate, consider implementing available options, including but not limited to, implementing a reverse stock split of its outstanding securities, to regain compliance with the Minimum Bid Price Requirement. If the Company does not regain compliance within the allotted compliance period, Nasdaq will pro”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.